post menopausal

Questions discussed in this category

What adjuvant therapy would you recommend for a 90-year-old woman with ER-positive, HER2-positive breast cancer who received neoadjuvant trastuzumab, pertuzumab, and anastrozole, but did not achieve a pathologic complete response?

1 Answer available

How would you approach treatment for a postmenopausal patient who was treated more than 5 years ago with AC-T for TNBC, and who now presents with ipsilateral, locally advanced, node-positive TNBC, but has severe residual neuropathy from prior taxane exposure?

1 Answer available

Papers discussed in this category

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2016-07-10

Selection of Optimal Adjuvant Chemotherapy Regimens for Human Epidermal Growth Factor Receptor 2 (HER2) -Negative and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline.

JAMA, 2019-01-22

Breast Cancer Treatment: A Review.

J Clin Oncol, 2021 Jan 28

Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.

N Engl J Med,

Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer.

JAMA oncology, 2024 Feb 01

Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer: NeoPACT Phase 2 Clinical Trial.

The New England journal of medicine, 2019-02-14

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer.

Related Topics